METHOD OF TREATMENT USING INHIBITORS OF MITOSIS

Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose. 147-. (canceled)48. A method of treating cancer by administering to a patient in need thereof two doses of (S)-2-(3-aminopropyl)-5-(2 ,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1 ,3 ,4-thiadiazole-3(2H)-carboxamide an inhibitor of mitosis selected from the group consisting of the '161 KSP Inhibitors between the biologically effective dose and the maximum tolerated dose in a 14 to 21 day dosing cycle , wherein the first dose is administered on day one of the dosing cycle and the second dose is administered on day two or day three of the dosing cycle.49. A method of claim 48 , wherein the dosing cycle is 14 days.50. A method of claim 48 , wherein the dosing cycle is 21 days.51. A method of claim 49 , wherein the second dose is administered on day two of the dosing cycle.52. A method of claim 50 , wherein the second dose is administered on day two of the dosing cycle.53. A method of claim 49 , wherein the second dose is administered on day three of the dosing cycle.54. A method of claim 50 , wherein the second dose is administered on day three of the dosing cycle.55. A method of claim 51 , wherein the two doses are at the maximum tolerated dose.56. A method of claim 52 , wherein the two doses are at the maximum tolerated dose.57. A method of claim 53 , wherein the two doses are at the maximum tolerated dose.58. A method of claim 54 , wherein the two doses are at the maximum tolerated dose.5970-. (canceled)71. A method of claim 55 , wherein the cancer is a hematological tumor.72. A method of claim 56 , wherein the cancer is a hematological tumor.73. A method of claim 57 , wherein the cancer is a ...